Table 2.

Inclusion and Exclusion criteria and endpoints of the included trials.

Study	Year	Inclusion criteria	Exclusion criteria	Primary endpoint	Secondary endpoints
Compare-Acute [13]	2017	Patients with STEMI and MVD (>50% stenosis of the N-IRA)	LM disease, CTO, severe valve disease, Killip class III or IV, severe stenosis and complications after IRA treatment.	MACCE (all-cause mortality, nonfatal MI, any revascularization, cerebrovascular events)	NACE (cardiac death, MI, any revascularization, CVA, major bleeding).
Hamza et al. [12]	2016	Diabetic patients with STEMI and MVD (at least 80% stenosis in N-IRA)	Prior CABG, LM disease and CTO.	Composite of all- cause mortality, recurrent MI, ischemia driven revascularization with PCI or CABG.	Individual component of primary end point, major bleeding and CIN
DANAMI 3- PRIMULTI [11]	2015	Patients with STEMI, MVD (>50% stenosis in the coronary artery)	Intolerance to contrast, cardiogenic shock, increase bleeding risk, stent thrombosis, indication for CABG	Composite of all- cause mortality, reinfarction, or ischemia driven revascularization of non-IRA.	Components of primary end-point, cardiac death, urgent and non urgent PCI of non-IRA
CvLPRIT [10]	2015	STEMI or LBBB with MVD (at least one N-IRAwith >70% lesion in one plane or >50% in 2 plane)	Previous Q-wave MI, prior CABG, cardiogenic shock, VSD or severe MR, CKD, thrombosis of previous stent, CTO	MACE (all-cause mortality, MI,HF, ischemia driven PCI OR CABG).	Components of primary endpoints, CV death, stroke, major bleeding, CIN
PRAGUE-13 (23)	2015	STEMI with successful PCI or IRA, at least 1 stenosis ofN-IRA > 70% with diameter > 2.5 mm, enrolment > 48h following onset of symptoms	Stenosis ofLM, hemodynamically significant valve disease, angina > 1 month prior to STEMI and cardiogenic shock.	All cause mortality, non- fatal MI and stroke.	Hospitalization for unstable angina, revascularization of non-infarct artery, CV mortality, hospitalization for HF, non-fatal MI and all-cause mortality
Tarasov et al. [42]	2014	STEMI with MVD (>70% stenosis ofat least two or more coronary arteries), target lesion amenable to PCI and target lesion located in native artery	Single lesions, acute heart failure Killip class III-IV, LM stenosis, small vessel <2.5 mm, thrombosis of prior stent	MACE (cardiac or non-cardiac death, re-infarction, repeat coronary revascularization.	Individual components of primary endpoints
PRAMI [9]	2013	STEMI and MVD (one or more >50% stenosis of the N-IRA)	Cardiogenic shock, prior CABG, LM disease or disease at ostia ofboth circumflex and LAD and CTO.	Composite of death from cardiac cause, nonfatal MI, refractory angina.	Death from non-cardiac cause, repeat revascularization (PC I and CABG)
Ghani et al. [43]	2012	STEMI with MVD (one or more stenosis in at least 2 major epicardial arteries or the combination of side branch and a main epicardial vessel provided that they supplied different territory	Patients with indication for urgent revascularization, >80 years old, prior CABG, CTO, LM disease, chronic A fib, limited life expectancy.	Ejection fraction at 6 months.	MACE (death, non-fatal re-infarction and additional revascularization).
Politi et al. [25]	2010	MVD (>70% stenosis of 2 or more epicardial coronary artery or major branches by visual estimate), ST elevation on EKG	Cardiogenic shock, LM disease, CABG, severe valve disease	MACE (CV and Non-CV death, in hospital death, re-infarction, re-hospitalization for ACS and repeat coronary revascularization	Length ofhospitalization and CIN
PRIMA [24]	2004	STEMI with successful PCI of IRA and at least 1 significant >70% stenosis of the coronary artery other than IRA	LM disease, cardiogenic shock, target lesion in N-IRA not suitable for PCI.	Absolute improvement in the LVEF, recovery time and magnitude of EF increase were assessed.	Safety of single stage PCI. All cause mortality, MI, urgent revascularization, bleeding, unstable angina and CV hospitalization.
HELP- AMI [44]	2004	STEMI with MVD (IRA and one or more lesion in N-IRA)	Lesion in vein graft, arterial conduits or in segments treated with angioplasty or stent implantation, recent thrombolysis, cardiogenic shock, single vessel disease, LM disease, CTO and side branch >2 mm which required to be covered by the stent.	Rate of repeat revascularization over a period of12 months.	Adverse in hospital events, procedural-cost

STEMI = ST elevation myocardial infarction, MVD = multi vessel disease, CTO = chronic total occlusion, LM = left main, N-IRA = non infarct related artery, IRA = infarct related artery, MI = myocardial infarction, CABG = coronary artery bypass grafting, CIN = contrast induced nephropathy, CVA = cerebrovascular accident, PCI = percutaneous coronary intervention, VSD = ventricular septal defect, MR = mitral regurgitation, ACS = acute coronary syndrome, HF = heart failure, MACCE = major adverse cardiovascular cerebrovascular events, NACE = net adverse clinical events.